Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ainos, Inc. - Common Stock
(NQ:
AIMD
)
0.4849
+0.0049 (+1.02%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,162
Open
0.4849
Bid (Size)
0.4700 (2)
Ask (Size)
0.4950 (10)
Prev. Close
0.4800
Today's Range
0.4849 - 0.4849
52wk Range
0.4000 - 1.500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose’s Potential in Chip Manufacturing and More
March 13, 2025
Via
ACCESS Newswire
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
March 11, 2025
Via
ACCESS Newswire
Performance
YTD
-3.02%
-3.02%
1 Month
-19.18%
-19.18%
3 Month
+2.11%
+2.11%
6 Month
-6.21%
-6.21%
1 Year
-64.35%
-64.35%
More News
Read More
Ainos Reports Full Year 2024 Financial Results
March 07, 2025
Via
ACCESS Newswire
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
March 07, 2025
Via
ACCESS Newswire
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
March 05, 2025
Via
ACCESS Newswire
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
January 27, 2025
Via
ACCESS Newswire
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
January 21, 2025
Via
ACCESS Newswire
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
December 18, 2024
Via
ACCESSWIRE
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
November 13, 2024
Via
ACCESSWIRE
Ainos Reports Third Quarter 2024 Financial Results
November 06, 2024
Via
ACCESSWIRE
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
January 17, 2025
Via
ACCESS Newswire
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
January 13, 2025
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 07, 2025
Via
Benzinga
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
December 18, 2024
Via
ACCESSWIRE
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
December 13, 2024
Via
ACCESSWIRE
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
October 28, 2024
Via
ACCESSWIRE
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
October 24, 2024
Via
ACCESSWIRE
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
September 24, 2024
Via
ACCESSWIRE
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
December 04, 2024
Via
ACCESSWIRE
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
November 11, 2024
Via
ACCESSWIRE
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
November 08, 2024
Via
ACCESSWIRE
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
October 07, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
October 03, 2024
Via
Benzinga
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
September 25, 2024
Via
ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
September 23, 2024
Via
ACCESSWIRE
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.